Basic Science and
Clinical Innovation
The U.S. National Institutes of Health – a crown jewel in medicine – has led basic cancer research, using competitive grants and consortia. Despite the brilliance of our scientists, the National Cancer Institute (NCI) estimates up to 20,000 potentially lifesaving cancer drugs are ready for human clinical trials but lack funding to move ahead.
* National Cancer Institute
To help scientists move projects into clinical trials, CanceRx provides capitalization, pilot manufacturing, trial design and management, regulatory submissions and selling rights for successful products. This approach frees scientists to focus on what they do best – discovery – while they gain royalties from successful products and pursue their quest to save lives.
Some cancer rates are trending down. For example, strong advocacy has fueled great progress on breast cancer. Smoking cessation has resulted in declining deaths from lung cancer. But there is less progress with other types of cancer. This fact highlights profound opportunities to save more lives with better prevention, diagnosis and treatment.
CanceRx uses a diversified long-term bond portfolio to finance clinical trial projects. Issuing bonds on credit markets is routine for many industries. Funding at this scale and diversification makes it possible to put many products at once into a commercial pipeline, increasing probabilities of success. This overall approach, based on work done at the Massachusetts Institute of Technology’s Sloan School of Management, will revolutionize biomedical research.
Improved Financing
of Clinical Development
The CanceRx financing model is underpinned by work from Dr. Andrew Lo and the Nobel Laureate faculty at MIT’s Laboratory for Financial Engineering. This approach uses bonds to fund long-term and multiple products in clinical development. This strategy statistically lowers risk and improves the investment attractiveness of drug candidates, filling a key gap in the commercialization pipeline.
Innovating
Collaborating
Accelerating
How CanceRx Is Better For Medical Researchers
| Phase | CanceRx Path | Traditional Path |
|---|---|---|
| Financing | CanceRx is funding clinical development | Fund a startup company |
| Research Priority | Scientists stay focused on academic science | Institutions manage regulatory, clinical manufacturing and study recruitment |
| Clinical Trials | Multiple trials continuously running | One trial or phase at a time |
| Trial Design | CanceRx designs trials using AI, companion diagnostics | Design trials in house or with service providers |
| Data Management | CanceRx documents trial dossiers | Researchers manage dossiers |
| Valuation | Phase II/III equity event | Attempt to sell at pre-clinical phase |
| Time to Market | Faster | Slower |
Getting In Touch
Please reach out to learn more about opportunities to partner with CanceRx.
By submitting this form, you are consenting to receive marketing emails from: CanceRx. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact